Hiroyuki Okuzawa | BiotechTV

top of page

ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging

Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new...

Company News

Jun 2

Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24

Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...

Company News

Jun 2, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page

ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging

Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24

Follow BiotechTV

Sponsors

Sponsor Spotlight